Illumina IPO
Illumina is a leading biotechnology company that develops, manufactures, and markets integrated systems for genetic analysis and DNA sequencing. The company's platforms are used in genomic research, clinical diagnostics, and applied markets including agriculture and consumer genomics. Illumina has been a key player in making DNA sequencing faster, more accurate, and cost-effective.
What We Know
Illumina went public in July 2000, trading on NASDAQ under the ticker symbol ILMN. The company's IPO raised approximately $93 million at $16 per share. Since going public, Illumina has grown significantly through both organic growth and strategic acquisitions, becoming the dominant player in the DNA sequencing market. The company has faced various challenges as a public company, including regulatory scrutiny over acquisitions and competitive pressures. Most notably, Illumina completed its acquisition of cancer detection company GRAIL in 2021, though it later faced regulatory pressure to divest the company. Despite these challenges, Illumina has maintained its position as a leader in genomics and continues to trade actively on public markets.
Frequently Asked Questions
Has Illumina had an IPO?
Yes, Illumina has been a public company since July 2000. The company went public on NASDAQ under the ticker symbol ILMN.
When is the Illumina IPO date?
Illumina already completed its IPO in July 2000, raising approximately $93 million at $16 per share. The company has been publicly traded for over two decades.
How can I buy Illumina stock?
You can buy Illumina stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol ILMN. The stock is widely available through online brokers and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts